Bridge to Life to Showcase Advances in Liver Transplantation at 2025 ILTS Congress in Singapore

Bridge to Life™ Ltd., a prominent name in organ preservation solutions and perfusion technology, has announced that it will present a series of significant abstracts at the upcoming 2025 International Congress of the International Liver Transplantation Society (ILTS) in Singapore. Taking place from May 28-31, this event is set to feature nine accepted abstracts underscoring the company’s commitment to advancing liver transplantation techniques.

One of the key presentations includes late-breaking research on the impact of machine perfusion on ischemia-reperfusion injury in liver transplantation, comprising a donor age-stratified analysis. This groundbreaking study, conducted by a team from Policlinico Universitario Fondazione Agostino Gemelli in Rome, Italy, aims to explore how donor age influences transplant outcomes when machine perfusion methods are applied.

Another late-breaking abstract will delve into the possibilities that machine perfusion presents for middle-volume centers, suggesting this technology could revolutionize practices in smaller transplant programs. This research is also from the same Italian team and highlights the growing accessibility of advanced perfusion techniques in various clinical settings.

Other presentations will explore the use of Hypothermic Oxygenated Perfusion (HOPE) in unusual scenarios, including cases involving pediatric patients. The potential of HOPE to enhance liver transplantation outcomes is being demonstrated through a case report from Birmingham Children's Hospital and Queen Elizabeth Hospital in the UK, emphasizing the importance of innovative solutions in expanded transplant criteria.

Further abstracts will present preliminary results on HOPE applications in pediatric liver transplants and its implications for patients with hepatocellular carcinoma. Research from Coimbra University Hospital Centre, Portugal, will analyze the recurrence rates of patients transplanted with grafts subjected to HOPE, while additional studies will address its application in acute on chronic liver failure situations.

In conjunction with these presentations, Bridge to Life will hold a workshop on May 28, 2025, focused on hands-on liver machine perfusion techniques. This workshop requires separate registration and aims to equip medical professionals with practical skills in utilizing machine perfusion technology.

Moreover, Bridge to Life will sponsor a symposium on May 29, discussing the challenges and opportunities related to expanding HOPE practices in the Asia-Pacific region. Esteemed speakers will include Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from Cleveland Clinic, and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital.

As a leader in the field, Bridge to Life manufactures a range of products aimed at improving organ preservation, including the Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. These solutions play a crucial role in enhancing the viability of organs for transplantation, demonstrating the company's dedication to product quality and innovation.

By featuring at the 2025 ILTS Congress, Bridge to Life aims to not only share its advancements but also to foster collaboration and knowledge exchange among experts in the liver transplantation community, thereby contributing to the ongoing evolution of this vital field.

Bridge to Life continues to set the standard for excellence in organ preservation, creating lasting impacts on the success of liver transplants and improving patient outcomes globally.